🌐 English में देखें
🆓 मुफ्त
🇮🇳 हिंदी
DrugCard
DrugCard क्या है?
DrugCard is an AI-enabled pharmacovigilance platform that automates local and global medical literature screening, helping pharmaceutical professionals detect adverse drug reactions faster and with fewer manual touchpoints across 100+ languages.
Traditional literature monitoring requires specialists to manually scan hundreds of journals per product per market — a process that typically consumes 11 minutes per article when done by hand. DrugCard reduces that to 1.5 minutes per article through AI-powered scanning, as validated in a 2024 study monitoring 113 open-access periodicals in Ukraine comprising 482 journal issues. The platform's proprietary OCR technology achieves up to 99% keyword recognition accuracy on scanned texts, including poorly digitized historical journals — a common bottleneck in Eastern European and Asian market submissions.
DrugCard is not the right fit for teams seeking a full end-to-end signal detection and risk assessment platform like ArisGlobal. It is specifically optimized for the literature screening stage of pharmacovigilance and does not replace clinical safety database management or regulatory submission tooling.
Traditional literature monitoring requires specialists to manually scan hundreds of journals per product per market — a process that typically consumes 11 minutes per article when done by hand. DrugCard reduces that to 1.5 minutes per article through AI-powered scanning, as validated in a 2024 study monitoring 113 open-access periodicals in Ukraine comprising 482 journal issues. The platform's proprietary OCR technology achieves up to 99% keyword recognition accuracy on scanned texts, including poorly digitized historical journals — a common bottleneck in Eastern European and Asian market submissions.
DrugCard is not the right fit for teams seeking a full end-to-end signal detection and risk assessment platform like ArisGlobal. It is specifically optimized for the literature screening stage of pharmacovigilance and does not replace clinical safety database management or regulatory submission tooling.
संक्षेप में
DrugCard is an AI Tool purpose-built for the literature monitoring stage of pharmacovigilance, delivering 70% time savings on journal scanning while maintaining traceable, audit-ready outputs for regulatory submissions. Its 100+ language support and coverage of 1,000+ journals across 55+ countries makes it viable for multi-market pharmaceutical operations without managing separate CRO contracts per region.
मुख्य विशेषताएं
AI-Enabled Data Intelligence
DrugCard's AI screening engine continuously monitors both indexed and non-indexed medical journals, automatically flagging publications that contain potential adverse event signals with a visual alert system. The February 2026 platform update introduced a priority-ranking algorithm that marks critical safety publications with a red alert icon, allowing specialists to triage by severity rather than chronology.
Multi-Language Support
The platform processes pharmacovigilance literature in over 100 languages, enabling pharmaceutical companies to run centralized monitoring programs across markets in Southeast Asia, Eastern Europe, and Latin America from a single interface rather than outsourcing to country-specific CROs for each region.
OCR Technology
DrugCard's proprietary OCR engine achieves up to 99% keyword recognition accuracy on scanned journal articles, including documents with poor scan quality, handwritten annotations, or non-standard fonts common in older regional medical publications. This eliminates the manual re-keying of content that frequently introduces transcription errors in traditional monitoring workflows.
Scalable and Flexible
New regional journals can be integrated into DrugCard's monitoring scope within 2–3 weeks of request, allowing pharmaceutical teams to add emerging markets to their monitoring program without extended implementation cycles. The platform also accommodates automated PubMed searches for global literature aggregation alongside its local journal coverage.
फायदे और नुकसान
✅ फायदे
- Time Efficiency — Pharmacovigilance teams using DrugCard consistently report 50–70% reductions in time spent on literature screening compared to manual workflows, with the 2024 Ukraine monitoring study demonstrating a reduction from 11 minutes to 1.5 minutes per article — a sevenfold productivity gain that frees specialists for higher-value analysis work.
- High Accuracy — The platform achieves 99% accuracy in keyword recognition across scanned texts, significantly reducing the false-negative rate that is a primary compliance risk in manual literature monitoring. Fewer missed adverse events means fewer regulatory findings during PSUR and PBRER audits.
- Cost-Effective — DrugCard eliminates the per-country CRO contract costs that accumulate when pharmaceutical companies outsource literature monitoring market by market. A single platform subscription covering 55+ countries consolidates billing and removes the coordination overhead of managing multiple vendors simultaneously.
- Improved Compliance — Every screening action in DrugCard is logged with timestamp, keyword parameters, and reviewer identity, creating a transparent audit trail that satisfies EMA, FDA, and ICH E2C(R2) documentation requirements without additional manual record-keeping.
❌ नुकसान
- Initial Learning Curve — Configuring DrugCard's monitoring scope — selecting journals, setting keyword parameters, and mapping product-market combinations — requires pharmacovigilance domain knowledge. Users without prior experience structuring literature monitoring protocols will need onboarding support from the DrugCard team before the platform delivers value at full capacity.
- Limited Customization — Highly specific monitoring requirements, such as custom signal detection algorithms or non-standard report output formats, may require direct consultation with DrugCard's implementation team rather than self-service configuration. Teams with unique workflow integrations into existing pharmacovigilance databases may encounter compatibility limitations not resolvable within the standard platform interface.
विशेषज्ञ की राय
DrugCard is the most operationally focused choice for MAHs and CROs running multi-country literature monitoring programs — particularly those dealing with non-indexed journals in Eastern European or Asian markets where competitor platforms lack coverage. The primary limitation is its scope: teams needing integrated signal detection, case processing, or regulatory filing within a single platform will need DrugCard alongside, not instead of, a broader pharmacovigilance suite.
अक्सर पूछे जाने वाले सवाल
DrugCard reduces per-article processing time from 11 minutes to approximately 1.5 minutes, a sevenfold efficiency gain validated in a 2024 study of 113 Ukrainian open-access periodicals. Overall, teams report 50–70% reductions in total literature monitoring hours, freeing pharmacovigilance specialists to focus on signal assessment and regulatory report preparation.
DrugCard is most cost-effective for organizations managing literature monitoring across multiple markets or products simultaneously. Small companies monitoring a single product in one region may not see ROI proportionate to the platform setup investment. The free Simple Search tool on the DrugCard website allows teams to test core AI screening functionality before committing to a full platform subscription.